Bupivacaine-fentanyl emergency group — Competitive Intelligence Brief

Bupivacaine-fentanyl emergency group (Bupivacaine-fentanyl emergency group) competitive landscape: 4 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Local anesthetic + opioid analgesic combination. Area: Anesthesia, Emergency Medicine, Pain Management.

marketed Local anesthetic + opioid analgesic combination Voltage-gated sodium channels (bupivacaine); mu opioid receptor (fentanyl) Anesthesia, Emergency Medicine, Pain Management Small molecule

Target snapshot

Bupivacaine-fentanyl emergency group (Bupivacaine-fentanyl emergency group) — Conrad Arnfinn Bjørshol. Bupivacaine provides local anesthesia by blocking sodium channels in nerve fibers, while fentanyl provides opioid analgesia by binding to mu opioid receptors.

Comparator set (4 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Bupivacaine-fentanyl emergency group TARGET	Bupivacaine-fentanyl emergency group	Conrad Arnfinn Bjørshol	marketed	Local anesthetic + opioid analgesic combination	Voltage-gated sodium channels (bupivacaine); mu opioid receptor (fentanyl)
bucain + fentanyl	bucain + fentanyl	University of Debrecen	marketed	Local anesthetic + opioid analgesic combination	Voltage-gated sodium channels (bucain); mu-opioid receptor (fentanyl)
Ropivacaine + Tramadol	Ropivacaine + Tramadol	Aga Khan University	marketed	Local anesthetic + opioid analgesic combination	Voltage-gated sodium channels (ropivacaine); mu-opioid receptor, norepinephrine transporter, serotonin transporter (tramadol)
Lidocaine 1% Injectable Solution, Sufentanil	Lidocaine 1% Injectable Solution, Sufentanil	University of Saskatchewan	phase 3	Local anesthetic + opioid analgesic combination	Voltage-gated sodium channels (lidocaine); mu-opioid receptor (sufentanil)
L-BUPIVACAINE ; MORPHINE	L-BUPIVACAINE ; MORPHINE	Corporacion Parc Tauli	phase 3	Local anesthetic + opioid analgesic combination	Voltage-gated sodium channels (L-bupivacaine); mu-opioid receptor (morphine)

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Local anesthetic + opioid analgesic combination class)

1. Aga Khan University · 1 drug in this class
2. Conrad Arnfinn Bjørshol · 1 drug in this class
3. Corporacion Parc Tauli · 1 drug in this class
4. University of Debrecen · 1 drug in this class
5. University of Saskatchewan · 1 drug in this class